| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEA8 |
| Uniprot No | P43361 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-318aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMLLGQKSQRYKAEEGLQAQGEAPGLMD VQIPTAEEQKAASSSSTLIMGTLEEVTDSGSPSPPQSPEGASSSLTVTDS TLWSQSDEGSSSNEEEGPSTSPDPAHLESLFREALDEKVAELVRFLLRKY QIKEPVTKAEMLESVIKNYKNHFPDIFSKASECMQVIFGIDVKEVDPAGH SYILVTCLGLSYDGLLGDDQSTPKTGLLIIVLGMILMEGSRAPEEAIWEA LSVMGLYDGREHSVYWKLRKLLTQEWVQENYLEYRQAPGSDPVRYEFLWG PRALAETSYVKVLEHVVRVNARVRISYPSLHEEALGEEKGV |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
nan
MAGEA8 (Melanoma-associated antigen A8) is a member of the MAGE protein family, a group of cancer-testis antigens (CTAs) primarily expressed in germline cells but re-expressed in various malignancies. Belonging to the MAGE-I subfamily, MAGEA8 shares structural features such as a conserved MAGE homology domain, which facilitates protein-protein interactions and modulates ubiquitin ligase complexes. First identified in melanoma, MAGEA8 is now linked to cancers including lung, liver, and gastric carcinomas, where its aberrant expression correlates with tumor progression and poor prognosis.
The biological role of MAGEA8 remains under investigation, though studies suggest involvement in transcriptional regulation, apoptosis evasion, and cell cycle control. Like other MAGE-I proteins, it may interact with E3 ubiquitin ligases like RING1B to alter substrate specificity, influencing pathways such as p53 signaling. Its restricted expression in normal tissues (primarily testes and placenta) and reactivation in tumors make it a potential immunotherapeutic target. Tumor-derived MAGEA8 peptides can bind HLA class I molecules, triggering cytotoxic T-cell responses without attacking healthy tissues.
Recombinant MAGEA8 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to produce purified, biologically active forms for research. Common variants include full-length proteins or functional domains fused with tags (e.g., His, GST) for purification and detection. Applications span antibody development, T-cell response assays, and mechanistic studies of oncogenesis. However, challenges persist, including variable immunogenicity across patients and potential off-target effects due to homology with other MAGE proteins. Ongoing research focuses on optimizing MAGEA8-targeted vaccines and combination therapies to enhance anticancer immunity.
×
